Clinical Trials

This is a 24-week Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three doses of crofelemer, a natural compound. Eligible volunteers will be randomized to receive crofelemer or placebo administered orally twice daily for the initial placebo-controlled treatment phase; thereafter for 20 weeks all participants will receive crofelemer.   Participants will be compensated for their time and inconvenience for up to $400.

Basic Study Requirements:

• Male or female aged 18 years or older
• HIV-1 infection confirmed by standard serological tests and/or viral load
• History of diarrhea of at least 1 month's duration

This is a 48-week, Phase 3, randomized, double-blinded, placebo-controlled study evaluating the effects of vicriviroc in combination with an optimized background regimen. The investigational drug, vicriviroc, inhibits entry of HIV into cells and is active against a variety of HIV strains, including antiretroviral-resistant strains. Eligible volunteers will be randomized in a 2:1 ratio to receive vicriviroc or placebo for 48 weeks. Participants will be compensated for their time and inconvenience.

Basic Study Requirements

• HIV-1-positive adult at least 18 years of age
• Viral load greater than 1,000 copies/ml

• Must be antiretroviral-experienced

If vicriviroc at the dosage studied proves to be safe and effective, study volunteers who successfully complete 48 weeks of treatment and for whom it is medically appropriate will be offered vicriviroc free of charge until the drug is commercially available. Volunteers will not be compensated for this part of the study.

This is a 10-week Phase 2/3 proof-of-concept, randomized, double-blinded, placebo-controlled study to evaluate the effects of Punica granatum (pomegranate) juice on the indices of quality of life and cardiac health in HIV-1-positive volunteers. Eligible volunteers will be randomized in a 1:1:1 ratio to receive one of two formulations of pomegranate juice (once daily, 8-ounce) or a placebo.   Volunteers who complete participation in the 10 week study and were in the placebo group will be re-randomized to receive one of two pomegranate juice formulations for another 8-weeks.   Volunteers will be compensated $25 per visit for their time and inconvenience..

Basic Study Requirements

• HIV-1-positive adult at least 18 years of age
• CD4 cell count greater than 350 cells/mm 3
• Treatment naïve or not currently on antiretroviral therapy for at least 90 days prior to the screening visit
• No current use of immune modulating therapies (i.e., IL-2, vaccine, Interferon gamma)

This study will help researchers to develop a rectal microbicide, a new HIV prevention strategy to be used during anal intercourse. This one visit study involves a computer-assisted interview focusing on the behaviors surrounding receptive anal intercourse, an anorectal examination, along with testing for sexually transmitted infections in compliance with local, state, and federal laws regarding sexually transmitted diseases. This study does not involve any medication or experimental procedures. Volunteers will be compensated $100 for one completed study visit for their time and inconvenience.

Basic Study Requirements

• Males or females at least 18 years of age
• HIV-negative or HIV-positive
• Either practices or does not practice receptive anal intercourse

Detecting HIV Genotypic Drug Resistance: HIV SpectraPoint

This is a Phase 1 pilot, proof-of-concept study to determine the efficacy of an in vitro diagnostic device, HIV SpectraPoint , in HIV-positive patients with prior resistance to antiretroviral medications. The primary objective of this study will compare the ability of SpectraPoint resistance technology to standard genotypic assay. This study requires one clinic visit with one blood draw. Volunteers may optionally return and discuss their resistance results with AIDS Research Alliance staff. Volunteers will be compensated $50 for their time and inconvenience.  

Basic Study Requirements: